
A scannable review of Oct. 5–9: Schneider Electric's $22.6 billion cash purchase of PTC, C.H. Robinson's $5.8 billion RXO deal, the completed Paramount–Warner Bros. Discovery merger, Sysco's $15.8 billion bond sale, Fed minutes that kept another hike in play, and PepsiCo's guidance cut.
| Issuer | Deal size | Market cap at IPO | Price vs. midpoint | First day | Return at 10/09 |
|---|---|---|---|---|---|
TRex Bio TRXB 4 | $117M | $422M | −7% | 0% | 0% |
Pine Tree Acquisition PAXGU 4 | $100M | $148M | 0% | 0% | 0% |
Retension Pharmaceuticals RTSN 4 | $45M | $114M | 0% | −12% | −12% |
DODC, an estimated $3 billion deal that reporting has put at a valuation of up to $20 billion; OPay $500M, vVardis $200M, Aspen Neuroscience $100M, Bambusa Therapeutics $100M, Centinel Spine $100M, Lycia Therapeutics $100M, Tang Capital Acquisition $75M, Simwon America $50M, Patriot Mobile $10M 4.SKYD 12. The deal valued WBD at about $110 billion 13.reuters.com
renaissancecapital.com
renaissancecapital.com
renaissancecapital.com
fiercebiotech.com
renaissancecapital.com
renaissancecapital.com
chrobinson.com
bnnbloomberg.ca
investors.devonenergy.com
newsroom.viatris.com
ir.energytransfer.com
federalreserve.gov
banking.senate.gov
terrainlabs.ai
cnbc.com
investors.levistrauss.com
ir.cbrands.com
tradingview.com
terrainlabs.ai
investors.sysco.com
investor.digitalrealty.com
reuters.com
renaissancecapital.com
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.